Kellerhals Carrard acted as legal counsel to the arranger, J&T IB and Capital Markets on all Swiss law-related matters of KKCG Financing 2 issuance of secured bonds worth €160 million. The bonds have a maturity
Tags :Kevin MacCabe
Kellerhals Carrard has advised J&T IB and Capital Markets on all Swiss law-related matters of the bond issuance (BI) for KKCG Financing. KKCG Financing issued secured bonds worth CZK 6 billion with a maturity
As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has
BKW enables pension funds to take out minority stakes in nine wind farms creating space for investments in renewable energies. The international energy and infrastructure company announced that it entered into a contract with Pensionskasse
Kellerhals Carrard advised BKW as borrower of its CHF 1.5 billion syndicated multicurrency revolving credit facility. BKW is an international energy and infrastructure company and offers integrated solutions in the fields of energy, buildings and infrastructure.
Fema Retail acquired all shares in Ladenbau Schmidt from the Schmidt family last 13th of May. The purchase price was highly leveraged by UBS Switzerland and additionally financed by a seller’s loan. Ladenbau Schmidt,
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a
The shareholders of Webland, a Swiss provider of webhosting, domain registration and xDSL services, have sold their shares together with their shares in the German Webland Internet Service Gesellschaft to the Swedish Miss Group. Kellerhals
Katadyn Group, a Swiss-based specialist in portable water filters and trekking food, has been acquired by a group of entrepreneurs led by Kontivia, a long-term, down-to-earth investment company and
Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At
